LGR5 ablation in intestinal crypt stem cells and colon cancer cells causes loss of F-actin, decreases cell–cell adhesion, and disrupts adhesion-associated proteins.[59] A recent study that targeted Lgr5+ cells with an antibody conjugated to cytotoxic drugs showed reduced tumor growth and proliferation in colon cancer.[60] Zhang et al[61] reported that monomethyl auristatin E linked with anti-LGR5 antibody-forming antibody-drug conjugate may diminish colorectal cancer tumors. Here, LGR5 is linked to colonic neoplasm.